Slough, United Kingdom
Slough, United Kingdom

Time filter

Source Type

Staben S.T.,Genentech | Heffron T.P.,Genentech | Sutherlin D.P.,Genentech | Bhat S.R.,Genentech | And 23 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2010

Starting from HTS hit 1a, X-ray co-crystallization and molecular modeling were used to design potent and selective inhibitors of PI3-kinase. Bioavailablity in this series was improved through careful modulation of physicochemical properties. Compound 12 displayed in vivo knockdown of PI3K pharmacodynamic markers such as pAKT, pPRAS40, and pS6RP in a PC3 prostate cancer xenograft model. © 2010 Elsevier Ltd. All rights reserved.


Heffron T.P.,Genentech | Berry M.,Genentech | Castanedo G.,Genentech | Chang C.,Genentech | And 20 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2010

Efforts to identify potent small molecule inhibitors of PI3 kinase and mTOR led to the discovery of the exceptionally potent 6-aryl morpholino thienopyrimidine 6. In an effort to reduce the melting point in analogs of 6, the thienopyrimidine was modified by the addition of a methyl group to disrupt planarity. This modification resulted in a general improvement in in vivo clearance. This discovery led to the identification of GNE-477 (8), a potent and efficacious dual PI3K/mTOR inhibitor. © 2010 Elsevier Ltd. All rights reserved.


Sutherlin D.P.,Genentech | Baker S.,Piramed Pharma | Bisconte A.,Genentech | Blaney P.M.,8 9 Spire Green Center | And 31 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2012

A potent inhibitor of PI3Kδ that is ≥200 fold selective for the remaining three Class I PI3K isoforms and additional kinases is described. The hypothesis for selectivity is illustrated through structure activity relationships and crystal structures of compounds bound to a K802T mutant of PI3Kγ. Pharmacokinetic data in rats and mice support the use of 3 as a useful tool compound to use for in vivo studies. © 2012 Elsevier Ltd. All rights reserved.


Heffron T.P.,Genentech | Wei B.,Genentech | Olivero A.,Genentech | Staben S.T.,Genentech | And 17 more authors.
Journal of Medicinal Chemistry | Year: 2011

Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3K has justly received the most attention for its potential in cancer therapy. Herein we report our successful approaches to achieve PI3K vs PI3K selectivity for two chemical series. In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3K that is not attained with the corresponding Lys777 of PI3K. In the benzoxepin series of inhibitors, the selectivity observed can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction. © 2011 American Chemical Society.


Sutherlin D.P.,Genentech | Bao L.,Genentech | Berry M.,Genentech | Castanedo G.,Genentech | And 27 more authors.
Journal of Medicinal Chemistry | Year: 2011

The discovery of 2 (GDC-0980), a class I PI3K and mTOR kinase inhibitor for oncology indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine. This substitution also increased the microsomal stability and the free fraction of compounds as evidenced through a pairwise comparison of molecules that were otherwise identical. Highlighted in detail are analogues of an advanced compound 4 that were designed to improve solubility, resulting in 2. This compound, is potent across PI3K class I isoforms with IC 50s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively, inhibits mTOR with a K i of 17 nM yet is highly selective versus a large panel of kinases including others in the PIKK family. On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clinical trials for cancer. © 2011 American Chemical Society.

Loading Piramed Pharma collaborators
Loading Piramed Pharma collaborators